Cargando…

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide

Haploidentical hematopoietic cell transplantation (haplo‐HCT) with posttransplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new‐onset posttransplant diabetes mellitus (PTDM) following haplo‐HCT are unknown. We examin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mangan, Brendan L., Patel, Dilan, Chen, Heidi, Gatwood, Katie S., Byrne, Michael T., Sengsayadeth, Salyka, Goodman, Stacey, Dholaria, Bhagirathbhai, Kassim, Adetola A., Jagasia, Madan, Chinratanalab, Wichai, Culos, Kathryn A., Engelhardt, Brian G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942195/ https://www.ncbi.nlm.nih.gov/pubmed/33709085 http://dx.doi.org/10.1002/jha2.70

Ejemplares similares

Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update
por: Patel, Dilan A., et al.
Publicado: (2020)

Six Month Freedom from Treatment Failure is an Important Endpoint for Acute Graft-Versus-Host Disease Clinical Trials
por: Sengsayadeth, Salyka, et al.
Publicado: (2013)

Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome
por: Kanda-Kato, Madoka, et al.
Publicado: (2020)

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022)

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
por: Solomon, Scott R., et al.
Publicado: (2016)

Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation
por: Katsanis, Emmanuel, et al.
Publicado: (2020)

HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
por: Bacigalupo, Andrea, et al.
Publicado: (2016)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure
por: Imanaga, Hiroshi, et al.
Publicado: (2020)

Posttransplant maintenance therapy in multiple myeloma: the changing landscape
por: Sengsayadeth, S, et al.
Publicado: (2017)

Similar Outcomes in Early-Failure Steroid-Dependent Compared to Upfront Steroid Refractory Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplant
por: Patel, Dilan A., et al.
Publicado: (2021)

The impact of Host vs. Graft mismatches on rejection of haploidentical bone marrow transplants in thalassemia patients using posttransplant cyclophosphamide
por: Marwah, Priya, et al.
Publicado: (2019)

Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm
por: Rieger, Max J., et al.
Publicado: (2023)

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐versus‐host disease prophylaxis
por: Hernani, Rafael, et al.
Publicado: (2021)

Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I
por: Yamashita, Motoi, et al.
Publicado: (2022)

Chimeric antigen receptor‐T cell therapies: The changing landscape
por: Sengsayadeth, Salyka M., et al.
Publicado: (2021)

Posttransplant infections
por: Thomas, Beje, et al.
Publicado: (2019)

Hyperglycemia in the Posttransplant Period: NODAT vs Posttransplant Diabetes Mellitus
por: Gupta, Suruchi, et al.
Publicado: (2018)

CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021)

Role of bridging therapy during chimeric antigen receptor T cell therapy
por: Bhaskar, Shakthi T., et al.
Publicado: (2021)

Idiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide: A Case Report
por: Liu, Wei-Hsin, et al.
Publicado: (2015)

Posttransplant Lymphoproliferative Disorders
por: Ibrahim, Hazem A. H., et al.
Publicado: (2012)

Posttransplant Metabolic Syndrome
por: Siddiqui, M. Shadab, et al.
Publicado: (2012)

Posttransplant autoimmune encephalitis
por: Cohen, Devon A., et al.
Publicado: (2018)

Posttransplant Intrarenal Lymphangiectasia
por: Kord, Ali, et al.
Publicado: (2020)

Posttransplant Complications and Comorbidities
por: Danziger-Isakov, Lara, et al.
Publicado: (2018)

Posttransplant Immune Activation: Innocent Bystander or Insidious Culprit of Posttransplant Accelerated Atherosclerosis
por: Ducloux, Didier, et al.
Publicado: (2017)

Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
por: Abe, Masaya, et al.
Publicado: (2021)

Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide
por: Mariotti, Jacopo, et al.
Publicado: (2019)

Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation
por: Wada, Fumiya, et al.
Publicado: (2023)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
por: Fierro-Pineda, Juan C., et al.
Publicado: (2023)

Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature
por: Farhan, Shatha, et al.
Publicado: (2016)

A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies
por: Nakamae, Hirohisa, et al.
Publicado: (2022)

Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant
por: Jimenez Jimenez, Antonio, et al.
Publicado: (2022)

Efflux capacity and aldehyde dehydrogenase both contribute to CD8(+) T-cell resistance to posttransplant cyclophosphamide
por: Patterson, Michael T., et al.
Publicado: (2022)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Identification of Cause of Posttransplant Cachexia by PCR
por: Guitard, Joelle, et al.
Publicado: (2012)

A Case of Posttransplant Fibrillary Glomerulonephritis
por: Ammayappan, Shiva Kumar, et al.
Publicado: (2023)

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies
por: Solh, Melhem M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e7gjv373qll1caduj633fe0m0i